Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors.

about

Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors.

Item

http://www.wikidata.org/entity/Q54119475

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Adverse reactions of sorafenib ...... ating digestive system tumors.

@en

Adverse reactions of sorafenib ...... ating digestive system tumors.

@nl

type

Item

label

Adverse reactions of sorafenib ...... ating digestive system tumors.

@en

Adverse reactions of sorafenib ...... ating digestive system tumors.

@nl

prefLabel

Adverse reactions of sorafenib ...... ating digestive system tumors.

@en

Adverse reactions of sorafenib ...... ating digestive system tumors.

@nl

P1476

Adverse reactions of sorafenib ...... eating digestive system tumors

@en

P2093

Jun Liang

http://www.w3.org/2001/XMLSchema#string

Li Lin

http://www.w3.org/2001/XMLSchema#string

Weiran Xu

http://www.w3.org/2001/XMLSchema#string

Xing Wei

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.

Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma.

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.

P304

542-547

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1759-7714.12608

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yali Fu

P577

2018-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29575544

http://www.w3.org/2001/XMLSchema#string

P932

5928375

http://www.w3.org/2001/XMLSchema#string